- Home
- NXTT vs EVAX Comparison
NXTT vs EVAX Comparison
Compare NXTT & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTT
- EVAX
- Stock Information
- Founded
- NXTT 2019
- EVAX 2008
- Country
- NXTT China
- EVAX Denmark
- Employees
- NXTT N/A
- EVAX N/A
- Industry
- NXTT
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXTT
- EVAX Health Care
- Exchange
- NXTT NYSE
- EVAX Nasdaq
- Market Cap
- NXTT 8.4M
- EVAX 8.7M
- IPO Year
- NXTT N/A
- EVAX 2021
- Fundamental
- Price
- NXTT $2.02
- EVAX $0.88
- Analyst Decision
- NXTT
- EVAX Strong Buy
- Analyst Count
- NXTT 0
- EVAX 2
- Target Price
- NXTT N/A
- EVAX $11.00
- AVG Volume (30 Days)
- NXTT 222.5K
- EVAX 77.4K
- Earning Date
- NXTT 11-15-2024
- EVAX 10-31-2024
- Dividend Yield
- NXTT N/A
- EVAX N/A
- EPS Growth
- NXTT N/A
- EVAX N/A
- EPS
- NXTT 3.59
- EVAX N/A
- Revenue
- NXTT $1,133,308.00
- EVAX $3,295,000.00
- Revenue This Year
- NXTT N/A
- EVAX $4,845.21
- Revenue Next Year
- NXTT N/A
- EVAX $30.30
- P/E Ratio
- NXTT $0.61
- EVAX N/A
- Revenue Growth
- NXTT N/A
- EVAX N/A
- 52 Week Low
- NXTT $0.94
- EVAX $0.87
- 52 Week High
- NXTT $6.66
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- NXTT 48.99
- EVAX 19.35
- Support Level
- NXTT $1.95
- EVAX $1.08
- Resistance Level
- NXTT $2.52
- EVAX $1.20
- Average True Range (ATR)
- NXTT 0.34
- EVAX 0.18
- MACD
- NXTT -0.07
- EVAX -0.01
- Stochastic Oscillator
- NXTT 9.09
- EVAX 1.11
About NXTT NEXT TECHNOLOGY HOLDING INC
Next Technology Holding Inc pursues two corporate strategies. One business strategy is to continue providing software development services, and the other strategy is to acquire and hold Bitcoin. It provides AI-enabled software development services to its customers, which include developing, designing, and implementing various SAAS software solutions for businesses of all types, including industrial and other businesses. Its bitcoin acquisition strategy generally involves acquiring bitcoin with its liquid assets that exceed working capital requirements, and from time to time, subject to market conditions, issuing debt or equity securities or engaging in other capital raising transactions to use the proceeds to purchase bitcoin.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.